These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 22741782)

  • 1. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
    Gaurav A; Singh R
    Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
    J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators.
    Gajjar KA; Gajjar AK
    Curr Drug Discov Technol; 2020; 17(1):100-118. PubMed ID: 30160214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
    Dowlati Beirami A; Hajimahdi Z; Zarghi A
    J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
    Babu S; Sohn H; Madhavan T
    Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
    Pourbasheer E; Aalizadeh R
    SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment.
    Zhao X; Chen M; Huang B; Ji H; Yuan M
    Int J Mol Sci; 2011; 12(10):7022-37. PubMed ID: 22072933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors.
    Bhatt HG; Patel PK
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3758-65. PubMed ID: 22546667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
    Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis - a case study on HIV-1 protease inhibitors.
    Sivan SK; Manga V
    J Mol Model; 2012 Feb; 18(2):569-82. PubMed ID: 21547550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
    Dessalew N; Patel DS; Bharatam PV
    J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore modeling, 3D-QSAR and docking study of 2-phenylpyrimidine analogues as selective PDE4B inhibitors.
    Tripuraneni NS; Azam MA
    J Theor Biol; 2016 Apr; 394():117-126. PubMed ID: 26804643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
    Chaube U; Bhatt H
    Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.
    Murumkar PR; Zambre VP; Yadav MR
    J Comput Aided Mol Des; 2010 Feb; 24(2):143-56. PubMed ID: 20179991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
    Buolamwini JK; Assefa H
    J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.